US4714681A
(en)
|
1981-07-01 |
1987-12-22 |
The Board Of Reagents, The University Of Texas System Cancer Center |
Quadroma cells and trioma cells and methods for the production of same
|
US4474893A
(en)
|
1981-07-01 |
1984-10-02 |
The University of Texas System Cancer Center |
Recombinant monoclonal antibodies
|
US5892019A
(en)
|
1987-07-15 |
1999-04-06 |
The United States Of America, As Represented By The Department Of Health And Human Services |
Production of a single-gene-encoded immunoglobulin
|
WO1989012624A2
(en)
|
1988-06-14 |
1989-12-28 |
Cetus Corporation |
Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
|
US4925648A
(en)
|
1988-07-29 |
1990-05-15 |
Immunomedics, Inc. |
Detection and treatment of infectious and inflammatory lesions
|
US5601819A
(en)
|
1988-08-11 |
1997-02-11 |
The General Hospital Corporation |
Bispecific antibodies for selective immune regulation and for selective immune cell binding
|
IL162181A
(en)
|
1988-12-28 |
2006-04-10 |
Pdl Biopharma Inc |
A method of producing humanized immunoglubulin, and polynucleotides encoding the same
|
US5116964A
(en)
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US5225538A
(en)
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
ZA902949B
(en)
|
1989-05-05 |
1992-02-26 |
Res Dev Foundation |
A novel antibody delivery system for biological response modifiers
|
ES2096590T3
(es)
|
1989-06-29 |
1997-03-16 |
Medarex Inc |
Reactivos biespecificos para la terapia del sida.
|
ATE139258T1
(de)
|
1990-01-12 |
1996-06-15 |
Cell Genesys Inc |
Erzeugung xenogener antikörper
|
US5314995A
(en)
|
1990-01-22 |
1994-05-24 |
Oncogen |
Therapeutic interleukin-2-antibody based fusion proteins
|
DE69127749T2
(de)
|
1990-03-20 |
1998-04-16 |
Univ Columbia |
Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
US5219837A
(en)
|
1990-06-21 |
1993-06-15 |
Trustees Of The University Of Pennsylvania |
Method of stimulating myelination of cells
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
ATE175118T1
(de)
|
1990-10-05 |
1999-01-15 |
Medarex Inc |
Gezielte immunostimulierung mit bispezifischen stoffen
|
US5858725A
(en)
|
1990-10-10 |
1999-01-12 |
Glaxo Wellcome Inc. |
Preparation of chimaeric antibodies using the recombinant PCR strategy
|
DE69128253T2
(de)
|
1990-10-29 |
1998-06-18 |
Chiron Corp |
Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
|
WO1992008495A1
(en)
|
1990-11-09 |
1992-05-29 |
Abbott Biotech, Inc. |
Cytokine immunoconjugates
|
EP0582595A1
(en)
|
1991-04-26 |
1994-02-16 |
Surface Active Limited |
Novel antibodies, and methods for their use
|
GB9115364D0
(en)
|
1991-07-16 |
1991-08-28 |
Wellcome Found |
Antibody
|
US5843749A
(en)
|
1991-07-26 |
1998-12-01 |
Regeneron Pharmaceuticals, Inc. |
Ehk and Ror tyrosine kinases
|
ES2193143T3
(es)
|
1992-03-05 |
2003-11-01 |
Univ Texas |
Uso de inmunoconjugados para la diagnosis y/o terapia de tumores vascularizaos.
|
US5855885A
(en)
|
1993-01-22 |
1999-01-05 |
Smith; Rodger |
Isolation and production of catalytic antibodies using phage technology
|
US7473423B2
(en)
|
1994-04-29 |
2009-01-06 |
Mayo Foundation For Medical Education And Research |
Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
|
AU722668B2
(en)
|
1994-12-30 |
2000-08-10 |
King's College London |
Methods for producing immunoglobulins containing protection proteins in plants and their use
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
AU716282B2
(en)
|
1995-06-07 |
2000-02-24 |
Johnson & Johnson Research Pty. Limited |
CDR-grafted anti-tissue factor antibodies and methods of use thereof
|
US6037454A
(en)
|
1996-11-27 |
2000-03-14 |
Genentech, Inc. |
Humanized anti-CD11a antibodies
|
US6133426A
(en)
|
1997-02-21 |
2000-10-17 |
Genentech, Inc. |
Humanized anti-IL-8 monoclonal antibodies
|
US6001575A
(en)
|
1997-03-19 |
1999-12-14 |
Johns Hopkins University |
Therapeutic uses of grip and grip-related molecules
|
US6287569B1
(en)
|
1997-04-10 |
2001-09-11 |
The Regents Of The University Of California |
Vaccines with enhanced intracellular processing
|
EP1032660B1
(en)
|
1997-11-17 |
2009-11-04 |
Micromet AG |
Method of identifying binding site domains that retain the capacity of binding to an epitop
|
HUP0101160A2
(hu)
|
1998-04-03 |
2001-08-28 |
Chugai Seiyaku Kabushiki Kaisha |
Humán szöveti faktor (TF) elleni humanizált antitest és eljárás előállítására
|
US6897044B1
(en)
|
1999-01-28 |
2005-05-24 |
Biogen Idec, Inc. |
Production of tetravalent antibodies
|
US6605709B1
(en)
|
1999-04-09 |
2003-08-12 |
Genome Therapeutics Corporation |
Nucleic acid and amino acid sequences relating to Proteus mirabilis for diagnostics and therapeutics
|
WO2001070266A2
(en)
|
2000-03-17 |
2001-09-27 |
Millennium Pharmaceuticals, Inc. |
Method of inhibiting stenosis and restenosis with a mixture of antibodies anti cd18 and anti ccr2
|
AU6842701A
(en)
|
2000-06-16 |
2002-01-14 |
Human Genome Sciences Inc |
Antibodies that immunospecifically bind to blys
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
US6586251B2
(en)
|
2000-10-31 |
2003-07-01 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
US20050144655A1
(en)
|
2000-10-31 |
2005-06-30 |
Economides Aris N. |
Methods of modifying eukaryotic cells
|
US7105348B2
(en)
|
2000-10-31 |
2006-09-12 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
US7214786B2
(en)
|
2000-12-14 |
2007-05-08 |
Kovalic David K |
Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
|
DE60211329T2
(de)
|
2001-01-16 |
2007-05-24 |
Regeneron Pharmaceuticals, Inc. |
Isolierung von sezernierte proteine exprimierenden zellen
|
US20090137416A1
(en)
|
2001-01-16 |
2009-05-28 |
Regeneron Pharmaceuticals, Inc. |
Isolating Cells Expressing Secreted Proteins
|
US20140072979A1
(en)
|
2001-01-16 |
2014-03-13 |
Regeneron Pharmaceuticals, Inc. |
Isolating cells expressing secreted proteins
|
US20140072980A1
(en)
|
2001-01-16 |
2014-03-13 |
Regeneron Pharmaceuticals, Inc. |
Isolating cells expressing secreted proteins
|
US7319139B2
(en)
|
2001-01-29 |
2008-01-15 |
Biogen Idec, Inc. |
TAG-72 specific CH2 domain deleted antibodies
|
US20030020733A1
(en)
|
2001-07-24 |
2003-01-30 |
Yin Memphis Zhihong |
Computer display having selective area magnification
|
JP2004538324A
(ja)
|
2001-08-03 |
2004-12-24 |
メディカル リサーチ カウンシル |
細胞内抗体
|
CN1622958B
(zh)
|
2001-08-23 |
2013-04-03 |
Rsr有限公司 |
促甲状腺素(tsh)受体的表位区域、其用途和针对该区域的抗体
|
IL161268A0
(en)
|
2001-11-07 |
2004-09-27 |
Agensys Inc |
Nucleic acid and corresponding protein entitled 161p2f10b and pharmaceutical and diagnostic compositions containing the same
|
EP1464702A4
(en)
|
2001-12-28 |
2005-09-21 |
Chugai Pharmaceutical Co Ltd |
METHOD FOR PROTEIN STABILIZATION
|
DE60329489D1
(de)
|
2002-02-13 |
2009-11-12 |
Ludwig Inst Cancer Res |
Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon
|
US7314974B2
(en)
|
2002-02-21 |
2008-01-01 |
Monsanto Technology, Llc |
Expression of microbial proteins in plants for production of plants with improved properties
|
US7193069B2
(en)
|
2002-03-22 |
2007-03-20 |
Research Association For Biotechnology |
Full-length cDNA
|
US7323553B2
(en)
|
2002-04-26 |
2008-01-29 |
Genentech, Inc. |
Non-affinity purification of proteins
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
WO2004009805A1
(ja)
|
2002-07-19 |
2004-01-29 |
Japan Science And Technology Agency |
新規抗体酵素生産方法、新規抗体酵素、およびその利用
|
DE60336406D1
(de)
|
2002-10-16 |
2011-04-28 |
Purdue Pharma Lp |
Antikörper, die an zellassoziiertes ca 125/0722p binden, und verfahren zu deren anwendung
|
EP1608684A2
(en)
|
2003-02-07 |
2005-12-28 |
Protein Design Labs, Inc. |
Amphiregulin antibodies and their use to treat cancer and psoriasis
|
US7605235B2
(en)
|
2003-05-30 |
2009-10-20 |
Centocor, Inc. |
Anti-tissue factor antibodies and compositions
|
AU2004242847B2
(en)
|
2003-05-31 |
2011-06-09 |
Amgen Research (Munich) Gmbh |
Pharmaceutical composition comprising a bispecific antibody for EpCAM
|
US7569389B2
(en)
|
2004-09-30 |
2009-08-04 |
Ceres, Inc. |
Nucleotide sequences and polypeptides encoded thereby useful for modifying plant characteristics
|
AU2003271174A1
(en)
|
2003-10-10 |
2005-04-27 |
Chugai Seiyaku Kabushiki Kaisha |
Double specific antibodies substituting for functional protein
|
EP2292664B1
(en)
|
2003-10-16 |
2016-11-23 |
Amgen Research (Munich) GmbH |
Multispecific deimmunized CD3-binders
|
US7612179B2
(en)
|
2003-11-28 |
2009-11-03 |
Astrazeneca Ab |
antibodies binding to a C-terminal fragment of apoliopoprotein E
|
PT1691837E
(pt)
|
2003-12-10 |
2012-08-27 |
Medarex Inc |
Anticorpos ip-10 e suas utilizações
|
US8298532B2
(en)
|
2004-01-16 |
2012-10-30 |
Regeneron Pharmaceuticals, Inc. |
Fusion polypeptides capable of activating receptors
|
ATE504599T1
(de)
|
2004-01-16 |
2011-04-15 |
Regeneron Pharma |
Zur aktivierung von rezeptoren fähige fusionspolypeptide
|
WO2005077982A1
(en)
|
2004-02-16 |
2005-08-25 |
Micromet Ag |
Less immunogenic binding molecules
|
DE602005018325D1
(de)
|
2004-02-19 |
2010-01-28 |
Genentech Inc |
Antikörper mit korrigierten cdr
|
US7192709B2
(en)
|
2004-03-15 |
2007-03-20 |
Digigenomics Co., Ltd. |
Methods for identification, assessment, prevention, and therapy of cancer
|
US7504086B2
(en)
|
2004-03-31 |
2009-03-17 |
Canon Kabushiki Kaisha |
Structure and method for releasing substance therefrom
|
WO2005100605A1
(en)
|
2004-04-06 |
2005-10-27 |
The Regents Of The University Of California |
Orphan receptor tyrosine kinase as a target in breast cancer
|
EP1749030B1
(en)
|
2004-04-22 |
2011-06-15 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
A diabody which specifically binds streptococcus surface antigen i/ii and methods of use thereof
|
JPWO2005105998A1
(ja)
|
2004-04-27 |
2008-07-31 |
財団法人化学及血清療法研究所 |
ヒト抗アミロイドβペプチド抗体およびその抗体フラグメント
|
UY28886A1
(es)
|
2004-05-10 |
2005-12-30 |
Boehringer Ingelheim Int |
Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
|
US7396530B2
(en)
|
2004-06-09 |
2008-07-08 |
Genentech, Inc. |
Method of treating granuloma annulare or sarcoid
|
BRPI0514478A
(pt)
|
2004-08-16 |
2008-06-17 |
Cropdesign Nv |
método para melhorar caracterìsticas de crescimento de plantas, plantas, construção, método para a produção de uma planta transgênica, planta transgênica, partes coletáveis, e, usos de um ácido nucleico/gene codificando proteìna de ligação de rna ou variante do mesmo ou uso de uma proteìna de ligação de rna ou homólogo da mesma, de um rbp1 ou variante do mesmo ou uso de um polipeptìdeo rbp1 ou homólogo do mesmo e de uma proteìna de ligação de rna ou variante da mesma ou uso de um rbp1 ou variante do mesmo
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ox40l抗體
|
CA2582683A1
(en)
|
2004-10-01 |
2006-04-13 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Novel antibodies directed to the mammalian eag1 ion channel protein
|
CA2591665C
(en)
|
2004-12-20 |
2015-05-05 |
Crucell Holland B.V. |
Binding molecules capable of neutralizing west nile virus and uses thereof
|
BRPI0607238B8
(pt)
|
2005-01-27 |
2021-05-25 |
Novimmune Sa |
anticorpos anti-interferon gama humano, usos dos mesmos na preparação de medicamentos e composições farmacêuticas
|
US8088976B2
(en)
|
2005-02-24 |
2012-01-03 |
Monsanto Technology Llc |
Methods for genetic control of plant pest infestation and compositions thereof
|
EP1865058B1
(en)
|
2005-03-31 |
2011-01-12 |
Biomedics Inc. |
Anti-cd-20 monoclonal antibody
|
JP5004154B2
(ja)
|
2005-04-06 |
2012-08-22 |
一般財団法人化学及血清療法研究所 |
組換え抗ボツリヌス神経毒素抗体
|
CN101163719A
(zh)
|
2005-04-22 |
2008-04-16 |
伊莱利利公司 |
TGFβ1特异性抗体
|
US20070124833A1
(en)
|
2005-05-10 |
2007-05-31 |
Abad Mark S |
Genes and uses for plant improvement
|
US7736647B2
(en)
|
2005-06-15 |
2010-06-15 |
Monoclonal Antibodies Therapeutics |
Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
|
RS55788B1
(sr)
|
2005-08-31 |
2017-08-31 |
Merck Sharp & Dohme |
Inženjerisana anti-il-23 antitela
|
WO2007051077A2
(en)
|
2005-10-28 |
2007-05-03 |
The Regents Of The University Of California |
Methods and compounds for lymphoma cell detection and isolation
|
WO2008103849A2
(en)
*
|
2007-02-21 |
2008-08-28 |
The Regents Of The University Of California |
Methods and compounds for lymphoma cell detection and isolation
|
US8716195B2
(en)
|
2005-11-14 |
2014-05-06 |
Bioren, Inc. |
Antibody ultrahumanization by predicted mature CDR blasting and cohort library generation and screening
|
TR201809912T4
(tr)
|
2006-02-14 |
2018-07-23 |
Bp Corp North America Inc |
Ksilanazlar, bunları kodlayan nükleik asitler ve bunları yapmak ve kullanmak için yöntemler.
|
JPWO2007102200A1
(ja)
|
2006-03-07 |
2009-07-23 |
国立大学法人大阪大学 |
抗cd20モノクローナル抗体
|
WO2007146957A2
(en)
|
2006-06-13 |
2007-12-21 |
Irm Llc |
Ror1 as a therapeutic target for lung cancer
|
AU2007284651B2
(en)
|
2006-08-09 |
2014-03-20 |
Institute For Systems Biology |
Organ-specific proteins and methods of their use
|
JP5517619B2
(ja)
|
2006-08-18 |
2014-06-11 |
ノバルティス アーゲー |
Prlr特異的抗体およびその使用
|
MX2009003229A
(es)
|
2006-09-29 |
2009-06-18 |
Oncomed Pharm Inc |
Composiciones y metodos para diagnosticar y tratar cancer.
|
EP2094307A4
(en)
|
2006-11-08 |
2015-08-26 |
Macrogenics West Inc |
TES7 AND THEREO BINDING ANTIBODIES
|
FR2909092B1
(fr)
|
2006-11-24 |
2012-10-19 |
Pf Medicament |
Nouveaux anticorps anti-proliferation
|
WO2008076868A2
(en)
|
2006-12-18 |
2008-06-26 |
Abbott Laboratories |
Methods and compositions related to modulation of receptor tyrosine kinase orphan receptor-1 (ror-1)
|
AU2007338670A1
(en)
|
2006-12-22 |
2008-07-03 |
Merck Sharp & Dohme Corp. |
Antibodies to CD200R
|
WO2008097439A2
(en)
|
2007-02-07 |
2008-08-14 |
The Trustees Of The University Of Pennsylvania |
Anti-autoimmune antibodies for treatment of pemphigus
|
US9745367B2
(en)
|
2007-03-23 |
2017-08-29 |
Novelmed Theraputics, Inc. |
Alternative pathway specific antibodies for treating arthritis
|
US8163279B2
(en)
|
2007-04-13 |
2012-04-24 |
Stemline Therapeutics, Inc. |
IL3Rα antibody conjugates and uses thereof
|
US20100129817A1
(en)
|
2007-05-03 |
2010-05-27 |
Regeneron Pharmaceuticals Inc. |
Identifying germline competent embryonic stem cells
|
KR101523788B1
(ko)
|
2007-05-17 |
2015-06-26 |
제넨테크, 인크. |
뉴로필린 단편 및 뉴로필린-항체 복합체의 결정 구조
|
AU2008272330A1
(en)
|
2007-07-04 |
2009-01-08 |
Forerunner Pharma Research Co., Ltd. |
Anti-Muc17 antibody
|
US8299318B2
(en)
|
2007-07-05 |
2012-10-30 |
Ceres, Inc. |
Nucleotide sequences and corresponding polypeptides conferring modulated plant characteristics
|
EP2183028A2
(en)
|
2007-07-25 |
2010-05-12 |
AstraZeneca AB |
Targeted binging agents directed to kdr and uses thereof - 035
|
CN101848999A
(zh)
|
2007-09-06 |
2010-09-29 |
国立大学法人大阪大学 |
抗-cd20单克隆抗体
|
US8362325B2
(en)
|
2007-10-03 |
2013-01-29 |
Ceres, Inc. |
Nucleotide sequences and corresponding polypeptides conferring modulated plant characteristics
|
HUE031533T2
(hu)
|
2007-10-19 |
2017-07-28 |
Seattle Genetics Inc |
CD19-kötõszerek valamint alkalmazásuk
|
US8715941B2
(en)
|
2007-11-16 |
2014-05-06 |
Arca Biopharma, Inc. |
Antibodies to LRP6
|
ES2834741T3
(es)
|
2007-12-05 |
2021-06-18 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-NR10 y uso del mismo
|
EP2594590B1
(en)
|
2007-12-14 |
2014-11-12 |
Bristol-Myers Squibb Company |
Method of producing binding molecules for the human OX40 receptor
|
AU2008338421A1
(en)
|
2007-12-17 |
2009-06-25 |
Dyax Corp. |
Compositions and methods for treating osteolytic disorders comprising MMP-14 binding proteins
|
EP2235058A2
(en)
|
2007-12-21 |
2010-10-06 |
Amgen, Inc |
Anti-amyloid antibodies and uses thereof
|
WO2009082485A1
(en)
|
2007-12-26 |
2009-07-02 |
Vaccinex, Inc. |
Anti-c35 antibody combination therapies and methods
|
WO2009097128A1
(en)
|
2008-01-29 |
2009-08-06 |
Ludwig Institute For Cancer Research Ltd. |
Membrane transporter napi2b (slc34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy
|
WO2009099580A2
(en)
|
2008-02-05 |
2009-08-13 |
Monsanto Technology, Llc |
Isolated novel nucleic acid and protein molecules from soy and methods of using those molecules to generate transgenic plants with enhanced agronomic traits
|
AR070316A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
|
ES2639857T3
(es)
|
2008-02-11 |
2017-10-30 |
Cure Tech Ltd. |
Anticuerpos monoclonales para el tratamiento del tumor
|
US8008445B2
(en)
|
2008-03-03 |
2011-08-30 |
Dyax Corp. |
Metalloproteinase 9 binding proteins
|
WO2009114335A2
(en)
|
2008-03-12 |
2009-09-17 |
Merck & Co., Inc. |
Pd-1 binding proteins
|
US8075885B2
(en)
|
2008-04-07 |
2011-12-13 |
Kalobios Pharmaceuticals, Inc. |
Methods of treating heart failure using an anti-GM-CSF antibody
|
US8314213B2
(en)
|
2008-04-18 |
2012-11-20 |
Xencor, Inc. |
Human equivalent monoclonal antibodies engineered from nonhuman variable regions
|
US9029508B2
(en)
|
2008-04-29 |
2015-05-12 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
US8410251B2
(en)
|
2008-06-20 |
2013-04-02 |
National University Corporation Okayama University |
Antibody against calcified globule and use of the same
|
US8187601B2
(en)
|
2008-07-01 |
2012-05-29 |
Aveo Pharmaceuticals, Inc. |
Fibroblast growth factor receptor 3 (FGFR3) binding proteins
|
CA2729747A1
(en)
|
2008-07-02 |
2010-01-07 |
Emergent Product Development Seattle, Llc |
Il6 immunotherapeutics
|
BRPI0916443A2
(pt)
|
2008-07-16 |
2017-10-31 |
Inst Res Biomedicine |
anticorpos de neutralização de citomegalovírus humanos e uso dos mesmos
|
JP5841332B2
(ja)
|
2008-07-18 |
2016-01-13 |
国立大学法人名古屋大学 |
細胞増殖阻害剤
|
US9074006B2
(en)
|
2008-07-31 |
2015-07-07 |
Basf Plant Science Gmbh |
Use of HUB1 polynucleotides for improving growth characteristics in plants
|
JP2012506695A
(ja)
|
2008-08-20 |
2012-03-22 |
ヤンセン バイオテツク,インコーポレーテツド |
改変された抗il−13抗体、組成物、方法、及び使用
|
US9855291B2
(en)
|
2008-11-03 |
2018-01-02 |
Adc Therapeutics Sa |
Anti-kidney associated antigen 1 (KAAG1) antibodies
|
US8183346B2
(en)
|
2008-12-05 |
2012-05-22 |
Eli Lilly And Company |
Anti-ferroportin 1 monoclonal antibodies and uses thereof
|
US9012723B2
(en)
|
2009-01-16 |
2015-04-21 |
Monsanto Technology Llc |
Isolated novel acid and protein molecules from soy and methods of using those molecules to generate transgene plants with enhanced agronomic traits
|
US8673307B1
(en)
|
2009-03-09 |
2014-03-18 |
The Rockefeller University |
HIV-1 anti-core neutralizing antibodies that target a conformational epitope within the ALPHA5-helix of GP120
|
WO2010107752A2
(en)
|
2009-03-20 |
2010-09-23 |
Amgen Inc. |
Alpha-4-beta-7 heterodimer specific antagonist antibody
|
EP2411412B1
(en)
|
2009-03-24 |
2015-05-27 |
Teva Biopharmaceuticals USA, Inc. |
Humanized antibodies against light and uses thereof
|
JP5757534B2
(ja)
|
2009-03-25 |
2015-07-29 |
ジェネンテック, インコーポレイテッド |
抗fgfr3抗体およびこれを用いた方法
|
WO2010117455A2
(en)
|
2009-04-08 |
2010-10-14 |
U.S. Army Medical Research Institute Of Infectious Diseases |
Human monoclonal antibodies protective against bubonic plaque
|
DK2419447T3
(en)
|
2009-04-17 |
2017-09-25 |
Immunas Pharma Inc |
ANTIBODIES THAT SPECIFICALLY BIND TO A BETA OLIGOMER AND USE THEREOF
|
WO2010124188A1
(en)
|
2009-04-23 |
2010-10-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-human ror1 antibodies
|
EP2424567B1
(en)
|
2009-04-27 |
2018-11-21 |
OncoMed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
DK2464664T3
(da)
|
2009-08-13 |
2016-01-18 |
Crucell Holland Bv |
Antistoffer mod humant respiratorisk syncytialvirus (rsv) og fremgangsmåder til anvendelse deraf
|
US8313747B2
(en)
|
2009-08-28 |
2012-11-20 |
Vlst Corporation |
Antikine antibodies that bind to multiple CC chemokines
|
EP2480572B1
(en)
|
2009-09-25 |
2019-01-30 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Neutralizing antibodies to hiv-1 and their use
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
ES2826883T3
(es)
|
2009-10-14 |
2021-05-19 |
Janssen Biotech Inc |
Métodos de maduración por afinidad de anticuerpos
|
CN102596996B
(zh)
|
2009-10-30 |
2014-06-18 |
东丽株式会社 |
对丙型肝炎病毒(hcv)具有感染抑制活性的抗体及其用途
|
US20120282177A1
(en)
|
2009-11-02 |
2012-11-08 |
Christian Rohlff |
ROR1 as Therapeutic and Diagnostic Target
|
SG10202110692WA
(en)
|
2009-11-11 |
2021-12-30 |
Ganymed Pharmaceuticals Gmbh |
Antibodies specific for claudin 6 (cldn6)
|
WO2011084496A1
(en)
|
2009-12-16 |
2011-07-14 |
Abbott Biotherapeutics Corp. |
Anti-her2 antibodies and their uses
|
EP2513146B1
(en)
|
2009-12-18 |
2017-05-03 |
Kancera AB |
Antibodies against ror1 capable of inducing cell death of cll
|
NZ601743A
(en)
|
2010-02-12 |
2014-11-28 |
Oncomed Pharm Inc |
Methods for identifying and isolating cells expressing a polypeptide
|
EP2542589A4
(en)
|
2010-03-04 |
2013-08-07 |
Symphogen As |
ANTIBODIES AND COMPOSITIONS ANTI-HER2
|
US8609095B2
(en)
|
2010-03-04 |
2013-12-17 |
Symphogen A/S |
Anti-HER2 antibodies and compositions
|
CN102918061B
(zh)
|
2010-03-05 |
2016-06-08 |
霍夫曼-拉罗奇有限公司 |
针对人csf-1r的抗体及其用途
|
WO2011123859A1
(en)
|
2010-04-02 |
2011-10-06 |
Skyfire Labs, Inc. |
Assisted hybrid mobile browser
|
EP2556085A2
(en)
|
2010-04-05 |
2013-02-13 |
Bar-Ilan University |
Protease-activatable pore-forming polypeptides
|
KR20130135028A
(ko)
|
2010-05-17 |
2013-12-10 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
동물로부터 단일클론 항체의 고속 분리
|
JO3330B1
(ar)
|
2010-06-10 |
2019-03-13 |
Lilly Co Eli |
الأجسام المضادة cgrp
|
JP2012021943A
(ja)
|
2010-07-16 |
2012-02-02 |
National Cancer Center |
子宮体がんの検査方法、子宮体がんの検査薬、並びに子宮体がん抗原に対する抗体
|
US9163258B2
(en)
|
2010-07-23 |
2015-10-20 |
Fred Hutchinson Cancer Research Center |
Method for the treatment of obesity
|
US9062115B2
(en)
|
2010-09-22 |
2015-06-23 |
Novo Nordisk A/S |
Therapeutic factor VIII antibodies
|
EP3219731A1
(en)
|
2010-10-01 |
2017-09-20 |
Oxford BioTherapeutics Ltd |
Anti-ror1 antibodies
|
US8790649B2
(en)
|
2010-10-29 |
2014-07-29 |
Immunogen, Inc. |
EGFR-binding molecules and immunoconjugates thereof
|
EP2455403A1
(en)
|
2010-11-23 |
2012-05-23 |
Pierre Fabre Medicament |
Homogeneous humanized antibodies against JAM-A that inhibit proliferation
|
JO3756B1
(ar)
|
2010-11-23 |
2021-01-31 |
Regeneron Pharma |
اجسام مضادة بشرية لمستقبلات الجلوكاجون
|
ES2657970T3
(es)
*
|
2010-12-01 |
2018-03-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anticuerpos contra ROR1 de conejo/ser humano quiméricos
|
GB201020995D0
(en)
|
2010-12-10 |
2011-01-26 |
Bioinvent Int Ab |
Biological materials and uses thereof
|
WO2012094587A1
(en)
|
2011-01-06 |
2012-07-12 |
Dyax Corp. |
Plasma kallikrein binding proteins
|
EP2663579B1
(en)
*
|
2011-01-14 |
2017-04-26 |
The Regents of the University of California |
Therapeutic antibodies against ror-1 protein and methods for use of same
|
CA2827301A1
(en)
|
2011-02-14 |
2012-08-23 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
WO2012118693A1
(en)
|
2011-02-28 |
2012-09-07 |
Northshore University Healthsystem |
Methods of diagnosing clostridium difficile infection
|
DK2699587T3
(da)
|
2011-04-22 |
2019-08-05 |
Wyeth Llc |
Sammensætninger med relation til et mutant-clostridium difficile-toksin og fremgangsmåder dertil
|
CN103748112B
(zh)
|
2011-05-13 |
2017-02-15 |
加尼梅德药物公司 |
用于治疗表达密蛋白6之癌症的抗体
|
WO2013019730A1
(en)
|
2011-07-29 |
2013-02-07 |
The Washington University |
Antibodies to tip-1 and grp78
|
US9102724B2
(en)
|
2011-08-12 |
2015-08-11 |
Omeros Corporation |
Anti-FZD10 monoclonal antibodies and methods for their use
|
HUE061002T2
(hu)
|
2011-09-23 |
2023-04-28 |
Mereo Biopharma 5 Inc |
VEGF/DLL4-kötõ ágensek és alkalmazásaik
|
CA2851814C
(en)
|
2011-10-13 |
2018-11-06 |
Bristol-Myers Squibb Company |
Antibody polypeptides that antagonize cd40l
|
EP2589609A1
(en)
|
2011-11-03 |
2013-05-08 |
Pierre Fabre Medicament |
Antigen binding protein and its use as addressing product for the treatment of cancer
|
EP2617319A1
(en)
|
2012-01-17 |
2013-07-24 |
Braun GmbH |
Head portion and handle portion of an oral care device
|
PT2818482T
(pt)
|
2012-02-21 |
2019-08-06 |
Toray Industries |
Composição farmacêutica para o tratamento de cancro
|
IN2014KN01715A
(pt)
|
2012-02-21 |
2015-10-23 |
Toray Industries |
|
EP2817338B1
(en)
|
2012-02-24 |
2017-07-26 |
AbbVie Stemcentrx LLC |
Dll3 modulators and methods of use
|
WO2013147153A1
(ja)
|
2012-03-29 |
2013-10-03 |
株式会社未来創薬研究所 |
抗lamp5抗体およびその利用
|
RU2640245C2
(ru)
|
2012-03-30 |
2017-12-27 |
Торэй Индастриз, Инк. |
Фармацевтическая композиция для лечения и/или предотвращения рака печени
|
JP6107655B2
(ja)
|
2012-03-30 |
2017-04-05 |
東レ株式会社 |
胆嚢癌の治療及び/又は予防用医薬組成物
|
JP6244350B2
(ja)
|
2012-04-03 |
2017-12-06 |
ノーベルメッド セラピューティクス インコーポレイテッド. |
ヒト化およびキメラ抗因子Bb抗体、ならびにその使用
|
AR090903A1
(es)
|
2012-05-01 |
2014-12-17 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-pmel17
|
JP2015523852A
(ja)
|
2012-05-14 |
2015-08-20 |
ジェネンテック, インコーポレイテッド |
腫瘍の診断と治療のための組成物と方法
|
CN103421113B
(zh)
|
2012-05-22 |
2018-01-19 |
武汉华鑫康源生物医药有限公司 |
抗BLyS抗体
|
JO3462B1
(ar)
|
2012-08-22 |
2020-07-05 |
Regeneron Pharma |
أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
|
PL3489261T3
(pl)
|
2012-08-24 |
2021-08-16 |
The Regents Of The University Of California |
Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
|
CN103792364B
(zh)
|
2012-10-31 |
2016-06-08 |
张宝弘 |
用于检测外周血中循环肿瘤细胞ror1蛋白的试剂及其应用
|
TW202206465A
(zh)
|
2012-11-14 |
2022-02-16 |
美商再生元醫藥公司 |
重組細胞表面捕捉蛋白質
|
AU2014218730B2
(en)
|
2013-02-22 |
2018-12-13 |
Abbvie Stemcentrx Llc |
Novel antibody conjugates and uses thereof
|
EP2789630A1
(en)
|
2013-04-09 |
2014-10-15 |
EngMab AG |
Bispecific antibodies against CD3e and ROR1
|
US20160106861A1
(en)
|
2013-04-26 |
2016-04-21 |
Spirogen Sarl |
Axl antibody-drug conjugate and its use for the treatment of cancer
|
PL3594240T3
(pl)
|
2013-05-20 |
2024-04-02 |
F. Hoffmann-La Roche Ag |
Przeciwciała przeciwko receptorowi transferyny i sposoby ich zastosowania
|
WO2015014376A1
(en)
|
2013-07-31 |
2015-02-05 |
Biontech Ag |
Diagnosis and therapy of cancer involving cancer stem cells
|
AU2014312210A1
(en)
|
2013-08-28 |
2016-04-07 |
Abbvie Stemcentrx Llc |
Engineered anti-DLL3 conjugates and methods of use
|
PE20160870A1
(es)
|
2013-11-06 |
2016-09-09 |
Abbvie Stemcentrx Llc |
Anticuerpos anti-claudina novedosos y metodos de uso
|
AU2014360811B2
(en)
|
2013-12-11 |
2017-05-18 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for the targeted modification of a genome
|
SG11201604784XA
(en)
|
2013-12-13 |
2016-07-28 |
Genentech Inc |
Anti-cd33 antibodies and immunoconjugates
|
PE20210648A1
(es)
|
2013-12-17 |
2021-03-26 |
Genentech Inc |
Anticuerpos anti-cd3 y metodos de uso
|
AU2014370404A1
(en)
|
2013-12-24 |
2016-07-07 |
Novelmed Therapeutics, Inc. |
Compositions and methods of treating ocular diseases
|
EP3107576A4
(en)
|
2014-02-21 |
2017-09-06 |
Abbvie Stemcentrx LLC |
Anti-dll3 antibodies and drug conjugates for use in melanoma
|
ME03407B
(me)
|
2014-04-01 |
2020-01-20 |
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh |
Klaudin-6 specifični imunoreceptori i t-ćelijsкi epitopi
|
BR112016024363A2
(pt)
|
2014-04-25 |
2017-10-10 |
Pf Medicament |
conjugado de anticorpo-fármaco e seu uso para tratamento de câncer
|